Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q1 2022 |
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
LIQUIDIA CORP | 4 | Q3 2023 | 49.0% |
ANIKA THERAPEUTICS INC | 4 | Q3 2023 | 14.6% |
STANDARD BIOTOOLS INC | 4 | Q3 2023 | 11.7% |
EVOLUS INC | 4 | Q3 2023 | 10.9% |
ALIMERA SCIENCES INC | 4 | Q3 2023 | 24.0% |
ADMA BIOLOGICS INC | 4 | Q3 2023 | 8.6% |
VERONA PHARMA PLC | 4 | Q3 2023 | 4.0% |
SOCIETAL CDMO INC | 4 | Q3 2023 | 2.0% |
AGIOS PHARMACEUTICALS INC | 4 | Q3 2023 | 0.1% |
EXELIXIS INC | 3 | Q3 2023 | 11.5% |
View Caligan Partners LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
ALIMERA SCIENCES INC | August 03, 2023 | 17,635,154 | 33.1% |
EXELIXIS, INC. | June 02, 2023 | 910,730 | 0.3% |
ADMA BIOLOGICS, INC. | December 09, 2022 | 10,264,311 | 4.6% |
AMAG PHARMACEUTICALS, INC. | November 16, 2020 | ? | ? |
Knowles Corp | September 30, 2019 | 102,674 | 0.0% |
View Caligan Partners LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
SC 13D/A | 2024-03-06 |
4 | 2024-02-22 |
13F-HR | 2024-02-14 |
SC 13D/A | 2024-01-08 |
4 | 2023-12-14 |
SC 13D/A | 2023-12-14 |
4 | 2023-11-29 |
13F-HR | 2023-11-14 |
4 | 2023-09-15 |
SC 13D/A | 2023-09-11 |
View Caligan Partners LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.